Genentech dives deeper into the microbiome, inking $534M deal with Microbiotica to develop IBD meds
Roche’s Genentech unit is doubling down on its study of the microbiome, inking a new deal today worth up to $500 million to develop meds …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
